COMPANY NEWS

Latest News

All the latest news & events from KaNDy Therapeutics.

Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the 25th Annual BIO-Europe Conference

Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the 25th Annual BIO-Europe Conference During the BIO-Europe conference taking place from 11-13 November in Hamburg, Dr Mary Kerr will be attending and participate in a panel discussion on the [...]

Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the SVB Leerink New Treatments Focused on Women’s Health Conference, New York

Dr Mary Kerr, CEO of KaNDy Therapeutics to present at the SVB Leerink New Treatments Focused on Women’s Health Conference, New York On the 10 October, Dr Mary Kerr will be attending and presenting at the SVB Leerink conference focusing on [...]

Dr Mary Kerr, CEO of KaNDy Therapeutics to present at Women’s Health Innovation Summit, Boston

In December (3rd-4th, 2019) 150 leaders in women’s health will be coming together in Boston at the Women’s Health Innovation Summit to drive innovation at the convergence of technology and healthcare. Dr Mary Kerr, CEO of KaNDY [...]

Waljit Dhillo, Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor at Imperial College London has joined KaNDy Therapeutics as a Scientific and Clinical Advisor.

Waljit Dhillo, Professor in Endocrinology & Metabolism, Consultant Endocrinologist and an NIHR Research Professor at Imperial College London has joined KaNDy Therapeutics as a Scientific and Clinical Advisor. Professor Dhillo will be [...]

KaNDy Therapeutics presents new compelling data with lead candidate NT-814 at The North American Menopause Society 2018 Annual Meeting

~ Treatment with NT-814 resulted in immediate improvements in bothersome post-menopausal symptoms~ ~ Phase Ib/IIa data showed rapid and significant reductions in the frequency and severity of hot flashes and the number of night time awakenings~ [...]

KaNDy Therapeutics successfully raises £25 million in a Series C financing. Funding to advance a breakthrough non-hormonal treatment for symptoms of the menopause, into a Phase 2b study in Q4 2018

Stevenage, UK, 29 August 2018 – KaNDy Therapeutics, a clinical-stage Women’s Health company, today announces it has successfully closed a Series C financing round, raising £25 million from new US investor Longitude Capital, and existing [...]

KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls

Stevenage, UK, 21 June 2018 – KaNDy Therapeutics, a UK clinical-stage biotech company, today announces the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls for both KaNDy Therapeutics and NeRRe Therapeutics, its sister [...]

KaNDy Therapeutics announces positive clinical data with lead candidate NT-814 for the treatment of symptoms of the menopause

~Phase Ib/IIa data showed rapid and highly significant reductions in the frequency and severity of hot flashes and the number of night time awakenings~ ~NT-814 is being developed to provide a valid alternative to hormone replacement therapy and [...]

KaNDy Therapeutics Managing Director to present at The Anglonordic Life Science Conference

24th May 2018: KaNDy Therapeutics Managing Director, Dr Mary Kerr, is invited to present at The Anglonordic Life Science Conference 11:00am -12.30pm in the Biotech Investment Room, County Hall, London  

Press Release: KaNDy Therapeutics launched to focus on a breakthrough new product in Women’s Health

First-in-class once daily NT-814 spun out of NeRRe Therapeutics into new company   Stevenage, UK, 27th September 2017 – KaNDy Therapeutics has been launched today to maximise the value of NT-814, a potential breakthrough medicine for [...]

Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt